Small Molecule Immunomodulators for T Cell Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and infectious diseases often face challenges due to T cell exhaustion, where chronic antigen stimulation leads to dysfunctional T cells, and existing therapies may not effectively address the PD-1/PD-L1 pathway inhibition to restore immune responses.
Innovation Solution
Development of compounds that inhibit the PD-1/PD-L1 and PD-L1/CD80 protein interactions, enhancing immune responses by blocking these interactions, thereby restoring T cell functionality and immune stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to block PD-1/PD-L1 interactions, then T cell activation is restored, but treatment complexity and cost increase
Solution Approach 1:
The patent employs small molecule compounds as temporary, reversible inhibitors of PD-1/PD-L1 interactions. These small molecules serve as disposable therapeutic agents that can be administered and metabolized, avoiding the complexity of monoclonal antibody production and administration while achieving the desired immunomodulatory effect through transient blockade of the PD-1 pathway.
Solution Approach 2:
The invention changes the molecular parameters from large protein-based monoclonal antibodies to smaller synthetic compounds with different pharmacokinetic and pharmacodynamic properties. This parameter change enables alternative administration routes, reduced manufacturing complexity, and different duration of action profiles while maintaining the core function of PD-1 pathway inhibition.
2Power
If chronic antigen stimulation is present, then immune response is initially strong, but T cells become exhausted and dysfunctional
Solution Approach 1:
The patent applies preliminary anti-action by preemptively blocking PD-1/PD-L1 interactions before T cell exhaustion becomes irreversible. The small molecule compounds prevent the formation of inhibitory PD-1/Ligand complexes that would otherwise lead to T cell dysfunction, thereby maintaining T cell responsiveness during chronic antigen stimulation rather than attempting to reverse established exhaustion.
Solution Approach 2:
The invention converts the harmful effect of chronic antigen stimulation into a beneficial therapeutic opportunity. By targeting the PD-1 pathway that becomes upregulated during chronic stimulation, the small molecule compounds transform the exhaustion mechanism into a therapeutic target, where blocking PD-1 restores T cell function despite the presence of chronic antigen drive.
Data Source
AI summary
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.